Tang Capital Management Increases Stake in Aurinia Pharmaceuticals to 10.0%

This Schedule 13D/A filing, dated June 4, 2026, reports an increased stake in Aurinia Pharmaceuticals Inc. (AUPH) by Tang Capital Management, LLC and associated reporting persons, including Kevin Tang. Following a series of open-market purchases between May 29, 2026, and June 2, 2026, the reporting group now beneficially owns 13,044,106 common shares, representing 10.0% of the company's outstanding stock. This is an increase from their previously reported position of 12,229,500 shares. The recent transactions included the purchase of 814,606 shares at weighted average prices ranging from approximately $15.28 to $15.35 per share. Additionally, the reporting persons disclosed potential obligations to purchase an additional 1,000,000 common shares via put option contracts with a strike price of $15.00, expiring in January 2027. Kevin Tang, a reporting person, currently serves as a member of Aurinia's Board of Directors and as its Chief Executive Officer. The acquisitions were made for investment purposes, with the group reserving the right to further adjust their holdings based on market conditions.